Evidence map›Paper›PMID 42158873›Full record

ArticleFrontiers in immunology2026

Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach.

Afif Nakhleh, Ahmad Mahamid, Yaniv Yechiel, Leonard Saiegh, Sagit Zolotov, Salomon M Stemmer

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Afif Nakhleh *Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, Haifa, Israel.
Ahmad Mahamid *Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Yaniv YechielRappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Leonard SaieghRappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Sagit ZolotovDiabetes and Endocrinology Clinic, Maccabi Healthcare Services, Haifa, Israel.
Salomon M StemmerDavidoff Center, Rabin Medical Center, Petah Tikva, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with limited therapeutic options following the failure of standard adjuvant therapies. We present a 54-year-old female with stage IV cortisol-secreting ACC that progressed despite radical adrenalectomy, adjuvant radiation, and mitotane therapy. Comprehensive genomic profiling revealed a complex molecular landscape: a "double hit" driving hypercortisolism (

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAntineoplastic Combined Chemotherapy ProtocolsHydrocortisoneAntibodies, Monoclonal, HumanizedFemaleHumansIpilimumabMiddle AgedMitotaneNeoplasm StagingPhenylurea CompoundsQuinolinesTreatment OutcomeAntibodies, Monoclonal, HumanizedHydrocortisoneIpilimumablenvatinibMitotanepembrolizumabPhenylurea CompoundsQuinolinesadrenocortical carcinomaimmunotherapyipilimumablenvatinibpembrolizumab

Identifiers

PMID42158873
PMCPMC13180886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.